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ABSTRACT 
Aim: Proliferative diabetic retinopathy (PDR) 
is a more serious clinical presentation of diabetic 
retinopathy. Panretinal photocoagulation (PRP) is an 
effective laser treatment for PDR. The heat from the laser 
shrinks the blood vessels to prevent them from re-
growing. However, in most cases, severe visual loss still 
develops despite therapy. The aim of this study was to 
examine the effect on visual acuity after PRP in PDR by 
conducting a systematic review. 
Methods: The search was systematically done 
on seven databases; MEDLINE, SCIENCE DIRECT, 
CINAHL COMPLETE, COCHRANE, SCOPUS, WEB 
OF SCIENCE and EMBASE. The search focused on any 
studies related to the effect of PRP on visual acuity in 
PDR. The search strategies were done by using keywords 
related to “Proliferative Diabetic Retinopathy”, 
“Panretinal Photocoagulation” and “Visual Acuity”.  
Results: A total of 1775 abstracts were initially 
identified. 575 abstracts were removed after duplication. 
The remaining of 1200 abstracts were reviewed by 
looking at the titles, abstracts and full papers using pre-
determined inclusion and exclusion criteria, after which 
only two were included in the review. These two studies 
showed that there is loss on visual acuity immediately 
after PRP treatment on PDR, but time to the recovery of 
vision varies from nine days to three months.  
Conclusion: There were only two studies on 
the effect of PRP on visual acuity in PDR. Therefore, 
more research which specifically focused on the effect of 
PRP should be carried out to investigate more on the 
effectiveness of the treatment.  
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Photocoagulation; Proliferative Diabetic 
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1. INTRODUCTION 
WHO (World Health Organisation) 
estimates that the global prevalence of Diabetes 
Mellitus (DM) will increase from 2.8% to 4.4% 
from the year 2000 to 2030 (Wild, Roglic et al. 
2004). In the latest report, the overall prevalence of 
Diabetes Mellitus was 11.6% and 14.9% in those 
aged above 18 years of age (Letchuman, Wan 
Nazaimoon et al. 2010) . Diabetic retinopathy is a 
common complication of diabetes mellitus and 
leading cause of blindness. From 93 million people 
worldwide, prevalence of proliferative diabetic 
retinopathy is 7%. (Yau, Rogers et al. 2012) . In 
Malaysia, the prevalence of Diabetic retinopathy 
among diabetics who are above 40 years with more 
than five years duration is higher, which is 14.6%. 
(Addoor, Bhandary et al. 2011). It exists to some 
degree in nearly all individuals who have had 
diabetes for more than 15 years, regardless of type. 
(Barber 2003). Risk factors that increase the 
prevalence are type 1 diabetes, increased levels of 
HBA1c, high blood pressure, and cholesterol. 
(Wong, Khan et al. 2008, Yau, Rogers et al. 2012)  
Photocoagulation is a standard treatment 
for proliferative diabetic retinopathy (PDR). It has 
been shown to induce regression of 
neovascularization and arrest of progression of 
diabetic retinopathy. (Dogru, Nakamura et al. 
1999). Typically, 1200 to 1600 laser burns 
(approximately 500 µm in size) on the retina are 
evenly spaced or scattered throughout the retinal 
tissue away from the macula and retinal pigment 
epithelium. (Bressler, Beck et al. 2011). All 
proliferative diabetic retinopathy eyes will receive 
panretinal photocoagulation therapy.  The pupils 
will be dilated with 2.5% phenylephrine and 1% 
tropicamide and argon laser light will delivered by 
a standard slit-lamp system (Coherent model 900 
argon laser) through a one-, quadrisperic or three-
mirror Goldmann-type contact lens. Each patient 
will receive argon-green on one eye (514 nm) laser 
burns, analogous to the DRS/ETDRS (Group 2004) 
protocol (with instruments set at a 100 to 500 um 
spot diameter, 250 to 750 mW power, and 0.1 to 
0.2 second duration. The laser area will be 
extended to 20° to 50° from the fovea. Complete 
PRP in high-risk eyes with angiographic evidence 
of disc and retinal neovascularization associated 
with retinal capillary non-perfusion, a target of 
approximately 1300–1500, 500 micron-sized burns 
spaced between one half and 1 burn width apart, 
beginning just outside the vascular arcades and 3 
disc diameters temporal to the macula, and 
extending to or just beyond the equator, are typical 
on the temporal side of the fundus. On the nasal 
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side of the fundus, burns begin about 1 disc 
diameter nasal to the optic disc and also extend to 
or just beyond the equator and it was divided into 
several sessions. Intensity and topography will be 
document by fundus photography using a fundus 
camera. (Group 2004)  Scatter laser 
photocoagulation is associated with moderate 
visual loss, some diminished visual field, reduced 
colour vision, and reduced contrast sensitivity. 
(Fong, Girach et al. 2007) 
The importance of the present systematic 
review is that there may be a short-term loss of 
visual acuity after panretinal photocoagulation. 
(Bressler, Beck et al. 2011). A temporary decrease 
in visual acuity is frequently noted after extensive 
scatter photocoagulation, with recovery to the pre-
treatment level in most cases within several weeks. 
(Danis and Davis 2008). 
The aim of this systematic review is to 
provide a comprehensive overview of the published 
literature pertaining to the effect of Panretinal 
Photocoagulation on visual acuity loss in 
proliferative diabetic retinopathy. 
2. METHODOLOGY 
2.1 Eligibility criteria 
The evidence database using establishes 
Preferred Reporting Items for Systematic Reviews 
and Meta-Analysis (PRISMA) statement was used 
to search the effect of Panretinal Photocoagulation 
on visual acuity in Proliferative Diabetic 
Retinopathy. A descriptive study involving a 
literature review of randomized clinical trials 
involving Panretinal Photocoagulation published 
was conducted. Indexing terms are similar between 
databases. The following inclusion criteria were 
applied to the abstracts to identify relevant studies: 
Both type 1 and type 2 diabetes were eligible for 
inclusion if they specifically addressed visual 
acuity and proliferative diabetic retinopathy.  Each 
and every abstract of the retrieved reports were 
read and evaluated. When there was uncertainty, 
the full paper was obtained to determine inclusion. 
Full papers were sourced for all abstracts deemed 
appropriate for inclusion. The full papers obtained 
were then read. The search terms used in the search 
were „‟Proliferative Diabetic Retinopathy‟‟, „‟Pan 
Retinal Photocoagulation‟‟ and „‟Visual Acuity‟‟. 
There were no date restrictions in the electronic 
searches for trials. The last search of the electronic 
databases was on the 1st August 2015. In this 
paper, there were case study and prospective study 
included. The participants were people with pre-
proliferative (DR) or proliferative diabetic 
retinopathy (PDR). Figure 1 shows the flow 
diagram of the study selection. 
 
 
Fig 1. Summary of the studies 
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2.2 Data sources and search strategies 
Articles were retrieved using seven electronic 
bibliographic databases of medical literature 
(Medline, Embase, Science Direct, Cochrane, 
Scopus, Web of Science and Cinahl Complete) 
were used by customized searches. The searches 
were limited to report studies on humans. The 
Publication Type ﬁlter was applied to exclude 
comments, letters, and editorial citations. In 
addition, the 64 additional articles identiﬁed from 
pilot electronic searches were hand-searched to 
identify articles incorrectly indexed and those 
awaiting indexing. The resulting abstracts were 
compiled in individual libraries using the software 
Endnote. Intra-search and inter-search duplicates 
were identiﬁed and removed. 
2.3 Study selection 
At this stage of the selection process, the emphasis 
is on excluding studies that clearly meet the 
exclusion criteria. Studies are eliminated from the 
endnote software if the titles and abstracts clearly 
disqualify them. The abstracts found in journal 
databases shows the statement of the problem, a 
description of participants, and specification of the 
experimental design. The screening process was 
performed independently and disagreements were 
resolved by asking co-researchers. We also 
excluded secondary complications of proliferative 
Diabetic Retinopathy such as glaucoma, tractional 
retinal detachment and vitreous haemorrhage, as 
they were beyond the scope of this review. 
2.4 Assessment of Risk Bias 
In this systematic review, Ferris et al., 1988 used 
case study as his study design and only 7 cases 
were included. Small sample size may have 
contributed to risk bias. The study is included once 
there is regression in visual in proliferative diabetic 
retinopathy after panretinal photocoagulation 
without any restriction on study design.  
2.5 Summary measurement  
This study was done qualitatively synthesised the 
effect of panretinal photocoagulation on visual 
acuity. Meta-analysis was not attempted due to 
exploration design of the study. 
3. RESULTS 
The electronic searches yielded a total of 
1775 references and entered in endnote. From 
Medline, a total of 201 articles were found, from 
Science Direct a total of 855 articles were found, 
from Cinahl complete a total of 43 articles were 
found, from Cochrane a total of 2 articles were 
found, from Scopus a total number of 285 articles 
were found, from Web of Science a total number 
86 articles were found and from Embase a total of 
303 articles were found. A total of 639 removed 
duplicate records, screened the remaining 1200 
records and removed 1183 references that were not 
relevant to the scope of the review. We reviewed 
17 full-text reports and included 2 reports of studies 
that were eligible for inclusion in the review. We 
were unable to assess 4 reports, either because the 
full-text copy was unavailable or because a 
translation was needed.  
Yoon et al. (1996) selected 21 patients 
with untreated severe diabetic retinopathy and PRP 
directed according to the ETDRS protocol in this 
study. The inclusion criteria included were visual 
acuity, clear media to permit PRP and slight 
macular thickening and no previous 
photocoagulation treatment. The patients go 
through PRP in two sittings one week apart. 
Photocoagulation enclosed the whole mid-
periphery beyond equator, and posterior to area 
enclosed by the temporal vascular arcades, nasal 
disc border and two disc diameter temporal to 
fovea. Green or blue-green argon laser used to treat 
all the eyes. Roughly, 1500-2000 burns of 100 or 
200 micron spot size were placed with 1/2-1 burn 
space apart through double aspheric lens. Before 
the treatment, complete ocular examination 
including visual acuity, intraocular pressure and 
fluorescein angiography were executed. All the 
variations in retinal sensitivity threshold values 
were measured from the numeric format. A paired 
t-test was applied to compare the results. 
In Ferris et al. (1988), there were seven 
case studies reviewed. Each of the case study has 
different stages of disease and different appearance 
but all of them gave a certain reading on visual 
acuity after PRP. The time of onset and duration of 
visual loss in the seven patients were different. Pre-
treatment visual acuity reduced to no light 
perception. All the patients were insulin dependent. 
Five of them develop diabetes before 20 years of 
age. However, all five of the patients experience 
return of visual acuity to within two Snellen lines 
of the pre-treatment level. Patient 1, 2 and 3 lost 
vision in three days or less. Patient 2 and 3 
regained vision in less than two weeks. Patients 4, 
5, 6 and 7 lost vision over one to four weeks and 
regained vision around three weeks to four months. 
On the whole all patients experience some degree 
of visual recovery within four months or less.  
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Table 1. Figure shows the flow diagram of the study selection 
 
First 
author 
Study Design Subjects Outcome 
measure 
Results 
No of 
participant 
Age Gender Duration of 
diabetic 
Yoon et 
al., 1996 
Prospective 
Study 
21 patients 38-74 
years 
Male: 13 
Female: 8 
7-32 years Visual 
acuity, 
retinal 
sensitivity 
The difference 
in visual acuity 
between pre-
treatment and 3 
months after 
treatment was 
not statistically 
significant. 
Ferris et 
al., 1988 
Case Study 7 patients 22-61 
years 
Male: 3 
Female: 4 
IDDM: 14-
30 years 
DM: 
2years 
Visual 
acuity 
Some degree of 
visual acuity 
recovery 
occurred in 4 
months or less 
in all patients 
 
4. DISCUSSION 
This study provides a comprehensive overview of the published literature concerning the effect of 
Panretinal Photocoagulation on visual acuity in proliferative diabetic retinopathy. Diabetic retinopathy is a 
serious and vision threatening complication of diabetes (Aiello 2014). There are various treatment modalities for 
diabetes such as close monitoring of blood glucose, blood pressure, HbA1c, regular follow up, intravitreal 
steroid. The ETDRS and the DRS have accepted pan-retinal photocoagulation as the gold-standard for treatment 
of proliferative diabetic retinopathy. (Giuliari 2012)  
The Diabetic Retinopathy Study has reported that eyes that received more laser burns showed a 
decreased risk of visual loss when compared to eyes that received less treatment. (Grunwald, Brucker et al. 
1989). (Yoon, Lee et al. 1996), showed that PRP is safe when the burn area is smaller as compared to larger 
ones. The ideal burn produced does not depend on only the spot size but also on the power and duration of the 
laser. The required power for a burn depends on the clarity of the media and the pigmentation of the fundus, 
even though spot-size setting and duration are kept constant. (Danis and Davis 2008). 
Multiple Random Control Trial, including the Diabetic Retinopathy Study and Early Treatment 
Diabetic Retinopathy Study, have shown that panretinal photocoagulation (Muraly, Limbad et al.) significantly 
reduces the risk of severe vision loss (best corrected visual acuity <5/200) from PDR by at least 50%. The 
adverse effects of laser can occur in three main ways. Firstly, the unintended laser absorption which is damage 
to cornea, pupil, lens or retina. Secondly, inadvertent coagulation will damage to central vision. Thirdly, injury 
to blood vessel will lead to bleeding into vitreous haemorrhage o r blockage. (Googe, Brucker et al. 2011)  The 
duration of the adverse effects may be transient (seven to 10 days) where they will experience headache and 
blurring of vision which may be due to raised intraocular pressure. In the medium term adverse effect which is 
three to six months there was only blurring of vision. Long term (permanent ) effects include which are reduced 
vision near and distance, poor night vision, poor colour vision, reduced peripheral vision preventing driving, 
light sensitivity (Muraly, Limbad et al. 2011). Patients should be aware that the cornea will be numb for a few 
hours. While laser photocoagulation treatment is well tolerated, with relatively rare serious adverse effects, and 
has excellent efficacy when applied appropriately, there is still opportunity to improve upon this great success.  
PRP was also studied by (McDonald and Schatz 1985) who found that the main causes of defective 
vision were macular edema (32%), vitreous haemorrhage (23%), tractional retinal detachment (14%), epiretinal 
membrane (9%), macular ischemia (7%), cataract, and neovascular glaucoma (5%). It was recently reported by 
(Soman, Ganekal et al. 2012) that (2.6%) developed significant vitreous haemorrhage, but none developed 
tractional retinal detachment or neovascular glaucoma. 
The use of anti-VEGF (vascular endothelial growth factor) were introduced by (Waisbourd, Goldstein 
et al. 2011). VEGF has been identiﬁed as having a major role in the pathogenesis of diabetic retinopathy (Simó 
and HERNandez 2009). Other treatment that may be effective to treat proliferative diabetic retinopathy is anti-
VEGF.  Panretinal photocoagulation remains the gold standard for treatment of proliferative diabetic retinopathy 
even though there is a temporary visual loss which may last for a few weeks. 
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5. CONCLUSION 
The aim of the treatment to prevent proliferation of blood vessel without any severe visual impairment. 
However, PRP may cause a temporary reduction in vision in the early post laser phase. This may be seen as 
early as one week after PRP and can normalize by 3 months. There were two studies on the effect of PRP on 
visual acuity in PDR. Therefore, more studies should be done to lessen the side effects of PRP. Panretinal 
photocoagulation is recommended treatment for patients and therefore, it is prudent to warn patients of this 
potential outcome. 
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